Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clash Looms Over IP Proposals As WHO's Draft Pandemic Treaty Moves Forward

Executive Summary

Measures to relax intellectual property protections are put forward in the “zero draft” of the World Health Organization's future pandemic treaty as well as in proposed amendments to the International Health Regulations, which describe how countries can prepare for and respond to health emergencies.

You may also be interested in...



First Draft Of WHO’s Pandemic Treaty: IP Waivers, Tech Transfer & Price Transparency

A World Health Organization negotiating body will shortly examine the “zero draft” of a proposed pandemic treaty aimed at better preparing the world for future health crises. But the international pharmaceutical industry claims the draft as currently worded could actually undermine equitable access to pandemic countermeasures.

EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’

Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel